Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 00003-0125
Drug Overview
NDC 00003-0125 is identified as Lialda (mesalamine) delayed-release tablets, 1.2g. Approved by the FDA for the induction and maintenance of remission in moderate to severe ulcerative colitis. It is marketed primarily by Shire (now part of Takeda).
Market Landscape
Market Size and Demand
The mesalamine market primarily caters to ulcerative colitis (UC) and Crohn’s disease (CD) patients. UC affects approximately 700,000 individuals in the US [1]. The segment embracing Lialda and comparable products includes chronic condition management, which necessitates ongoing treatment.
Key factors influencing demand:
- Rising UC prevalence: Estimated to grow by 3.3% annually in developed markets [2].
- Treatment guidelines: Favor maintenance therapies like mesalamine for remission, driving consistent demand.
- Competitive products: Uni-based formulations such as Asacol (mitozolamine), Apriso, and generic mesalamine alternatives.
Competitive Landscape
Major competitors:
- Pentasa (asacol, 5-aminosalicylic acid): Similar formulation, broader indications.
- Apriso (mesalamine 0.375g): Extended-release, once-daily dosing.
- Generic mesalamine: Significant price competition, often used off-label or as lower-cost alternatives.
Market share is concentrated among branded products, but generics and biosimilars pose downward pressure. Takeda controls a substantial segment due to early market entry and brand recognition.
Price Projections
Historical Pricing Trends
- Branded mesalamine (Lialda): Wholesale acquisition cost (WAC) for a 28-count box (30mg tablets) averaged around $600-$750 in 2022 [3].
- Generic formulations: Prices fall to approximately $200-$400, with significant variability based on supplier and discounting strategies.
Current Pricing
- If priced at WAC, the monthly cost for branded Lialda (30mg, 60 tablets per month) remains around $600-$750.
- Insurance coverage and commercial discounts often reduce this by 20-50%.
Future Price Trends
- Patent expiration: The patent for Lialda expired in 2022 in the US [4]. Generic versions are expected to capture market share, further reducing prices.
- Market dynamics:
- Prediction: Generic mesalamine price discounts of 20-50% over the next 2-3 years.
- Potential for disruptive biosimilars or novel formulations to appear by 2024-2025.
- Pricing trajectory estimate:
- Short-term (next 12 months): Stability with slight reductions of 10-15% due to payer negotiations and market saturation.
- Medium-term (2-3 years): 30-50% price decrease as generics gain traction.
Policy and Regulatory Factors Influencing Price
- Medicare Part D and Medicaid: Price caps and negotiations influence paid price.
- FDA approval pathways: Abbreviated New Drug Applications (ANDA) facilitating rapid generic entry.
- State and federal price regulations: Increased scrutiny on drug pricing affects retail and wholesale costs.
Key Market Drivers and Risks
| Drivers |
Risks |
| Increasing UC prevalence |
Stringent price controls and reimbursement limits |
| Patent expiry of branded product |
Entrenchment of generics reducing prices |
| Established formulary inclusion |
Market saturation from cheap generics |
| Clinical guidelines favoring mesalamine |
Potential competition from new treatment modalities |
Summary
The mesalamine market, including NDC 00003-0125, experiences persistent demand driven by chronic UC management. The pricing is stable at premium levels for branded products but faces pressure from generics. Price erosion of 30-50% over the next 2-3 years is expected due to patent expirations and increased generic competition.
Key Takeaways
- Lialda remains a key product in mesalamine therapy but faces rapid market shift from generics.
- The current WAC price indicates an $600-$750 monthly cost, with significant discounts available through payers.
- Generics are expected to lower prices by approximately 30-50% within three years.
- Market growth is steady but constrained by pricing pressures, competition, and policy changes.
- Innovation in formulation and new indications could influence future pricing and market share.
FAQs
Q1: When did the patent for Lialda expire?
A1: The patent expired in 2022, opening the market to generic competition [4].
Q2: How much is the average cost of generic mesalamine?
A2: Approximately $200-$400 per month, depending on sources and discounts.
Q3: What factors could accelerate price reductions?
A3: Increased generic market entry, payor negotiations, and policy measures regulating drug prices.
Q4: What are the main competitors to Lialda?
A4: Asacol (mesalamine formulations), Apriso, and other generic mesalamine products.
Q5: How will biosimilars impact the mesalamine market?
A5: Biosimilars typically have limited impact, as mesalamine is small-molecule, but they can influence overall pricing dynamics indirectly.
Citations
- Centers for Disease Control and Prevention (CDC). "Ulcerative Colitis Prevalence." 2022.
- Global Data, "Ulcerative Colitis Market Reports," 2022.
- GoodRx. "Mesalamine prices," 2022.
- FDA. "Approval History of Lialda," 2022.
